Effectiveness following switch from other TPO-RA

A retrospective, observational study included both primary (25/44) and secondary (19/44) ITP patients. The results presented only refer to those patients with primary ITP from supplementary data.¹23% of patients switched from eltrombopag to Doptelet and 75% switched from romiplostim. One patient had previous experience with both eltrombopag and romiplostim.¹

Switching to Doptelet produced an effective response^1,2

Patients who do not have an adequate response to their TPO-RA treatment may benefit from switching to a different TPO-RA, as recommended by ICR guidelines.^1,3

Switching to Doptelet reduced the need for concomitant steroids¹

In a retrospective, observational study, 43% (19/44) of patients were receiving concomitant corticosteroids before switching to Doptelet. For primary patients, the figure is 40% (10/25).¹

Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).²

ICR, international consensus report; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

References

1. Al-Samkari H et al. Br J Haematol. 2022; 197(3):359–366. 2. Doptelet EMC Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11837/smpc#gref Last accessed: September 2023. 3. Provan D et al. Blood Adv. 2019; 3(22):3780–3817.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (for United Kingdom) and www.hpra.ie (for Republic of Ireland). Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754

PP-18708
Jan, 2025